HRP20140071T1 - Derivat piperidinila kao modulator aktivnosti receptora kemokina - Google Patents
Derivat piperidinila kao modulator aktivnosti receptora kemokina Download PDFInfo
- Publication number
- HRP20140071T1 HRP20140071T1 HRP20140071AT HRP20140071T HRP20140071T1 HR P20140071 T1 HRP20140071 T1 HR P20140071T1 HR P20140071A T HRP20140071A T HR P20140071AT HR P20140071 T HRP20140071 T HR P20140071T HR P20140071 T1 HRP20140071 T1 HR P20140071T1
- Authority
- HR
- Croatia
- Prior art keywords
- active substances
- acid
- additional active
- compound
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7539408P | 2008-06-25 | 2008-06-25 | |
| US12/490,477 US8299098B2 (en) | 2008-06-25 | 2009-06-24 | Piperidinyl derivative as a modulator of chemokine receptor activity |
| PCT/US2009/048564 WO2009158452A1 (en) | 2008-06-25 | 2009-06-25 | Piperidinyl derivative as a modulator of chemokine receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140071T1 true HRP20140071T1 (hr) | 2014-02-14 |
Family
ID=41060069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140071AT HRP20140071T1 (hr) | 2008-06-25 | 2009-06-25 | Derivat piperidinila kao modulator aktivnosti receptora kemokina |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8299098B2 (https=) |
| EP (1) | EP2323983B1 (https=) |
| JP (1) | JP5357965B2 (https=) |
| KR (1) | KR20110023865A (https=) |
| CN (1) | CN102076663B (https=) |
| AU (1) | AU2009262219B2 (https=) |
| BR (1) | BRPI0914539A2 (https=) |
| CA (1) | CA2729016A1 (https=) |
| CL (1) | CL2010001566A1 (https=) |
| CO (1) | CO6321247A2 (https=) |
| CY (1) | CY1114994T1 (https=) |
| DK (1) | DK2323983T3 (https=) |
| EA (1) | EA021224B1 (https=) |
| ES (1) | ES2447740T3 (https=) |
| HR (1) | HRP20140071T1 (https=) |
| IL (1) | IL209832A (https=) |
| MX (1) | MX2010013664A (https=) |
| NZ (1) | NZ589909A (https=) |
| PE (1) | PE20110103A1 (https=) |
| PL (1) | PL2323983T3 (https=) |
| PT (1) | PT2323983E (https=) |
| SI (1) | SI2323983T1 (https=) |
| TW (1) | TWI433838B (https=) |
| WO (1) | WO2009158452A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| US8410139B2 (en) * | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| CN102648193A (zh) * | 2009-10-07 | 2012-08-22 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的螺环化合物 |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| WO2013013114A1 (en) | 2011-07-21 | 2013-01-24 | Bristol-Myers Squibb Company | Bioavailable compositions of amorphous piperidinyl compounds |
| WO2013162984A1 (en) | 2012-04-25 | 2013-10-31 | Bristol-Myers Squibb Company | Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist |
| US9257178B1 (en) * | 2014-11-26 | 2016-02-09 | Taiwan Semiconductor Manufacturing Company Limited | Devices and methods for writing to a memory cell of a memory |
| EP3507830A4 (en) * | 2016-08-31 | 2020-04-01 | Micron Technology, Inc. | MEMORY CELLS AND MEMORY MATRICES |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60163855A (ja) | 1984-02-06 | 1985-08-26 | Mitsubishi Chem Ind Ltd | アルギニン誘導体および薬剤として許容され得るその酸付加塩 |
| GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
| DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
| WO1997003060A1 (en) | 1995-07-13 | 1997-01-30 | Senju Pharmaceutical Co., Ltd. | Piperazine derivatives and use of the same |
| JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1998017625A1 (en) | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
| US5847148A (en) | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
| JPH1171350A (ja) * | 1997-06-17 | 1999-03-16 | Takeda Chem Ind Ltd | ヒドロキシピペリジン化合物およびその剤 |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| DE69939165D1 (de) | 1998-04-16 | 2008-09-04 | Encysive Pharmaceuticals Inc | N,n-disubstituierte amide welche die bindung von integrinen an ihre rezeptoren hemmen |
| PT1140830E (pt) | 1998-12-17 | 2005-08-31 | Wyeth Corp | Derivados de arilpiperidina e aril-1,2,5,6-tetra-hidro-piridina amida possuindo actividade receptora de 5ht1a |
| US6489354B1 (en) | 1999-03-02 | 2002-12-03 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| WO2001098268A2 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
| DE10049699A1 (de) * | 2000-10-07 | 2002-05-08 | Bosch Gmbh Robert | Anker für eine elektrische Maschine sowie Verfahren zu dessen Herstellung |
| WO2002059117A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| JP2004532838A (ja) | 2001-03-02 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物 |
| US6887924B2 (en) | 2001-05-11 | 2005-05-03 | Multisorb Technologies, Inc. | Pressed adsorbent and method of fabrication thereof |
| DE10124041A1 (de) | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
| JP4336196B2 (ja) | 2001-07-18 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| AR036492A1 (es) | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| CN101973998A (zh) | 2001-12-20 | 2011-02-16 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物 |
| US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| DK1531822T3 (da) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0224917D0 (en) | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| AU2003284165B2 (en) | 2002-10-30 | 2008-12-11 | Merck Sharp & Dohme Corp. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| EP1633737A1 (en) | 2003-06-13 | 2006-03-15 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| FR2862967B1 (fr) | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| DE10358539A1 (de) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
| SE0400208D0 (sv) * | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2006004741A2 (en) | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| JP4116670B2 (ja) | 2004-06-28 | 2008-07-09 | インサイト コーポレイション | ケモカイン受容体の調節剤としての３−アミノシクロペンタンカルボキサミド |
| US7723360B2 (en) | 2004-08-06 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Alkyl-and piperidine-substituted benzimidazole derivatives |
| EP1853583B1 (en) * | 2005-02-16 | 2011-09-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| EP2173713B1 (en) | 2007-07-24 | 2016-02-17 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8536198B2 (en) | 2007-07-24 | 2013-09-17 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| WO2013013114A1 (en) | 2011-07-21 | 2013-01-24 | Bristol-Myers Squibb Company | Bioavailable compositions of amorphous piperidinyl compounds |
-
2009
- 2009-06-17 TW TW098120298A patent/TWI433838B/zh not_active IP Right Cessation
- 2009-06-24 US US12/490,477 patent/US8299098B2/en active Active
- 2009-06-25 BR BRPI0914539A patent/BRPI0914539A2/pt not_active IP Right Cessation
- 2009-06-25 SI SI200930827T patent/SI2323983T1/sl unknown
- 2009-06-25 CN CN2009801245643A patent/CN102076663B/zh not_active Expired - Fee Related
- 2009-06-25 PE PE2010001176A patent/PE20110103A1/es not_active Application Discontinuation
- 2009-06-25 ES ES09770985.1T patent/ES2447740T3/es active Active
- 2009-06-25 EP EP09770985.1A patent/EP2323983B1/en not_active Not-in-force
- 2009-06-25 KR KR1020107029082A patent/KR20110023865A/ko not_active Withdrawn
- 2009-06-25 WO PCT/US2009/048564 patent/WO2009158452A1/en not_active Ceased
- 2009-06-25 NZ NZ589909A patent/NZ589909A/en not_active IP Right Cessation
- 2009-06-25 PT PT97709851T patent/PT2323983E/pt unknown
- 2009-06-25 HR HRP20140071AT patent/HRP20140071T1/hr unknown
- 2009-06-25 AU AU2009262219A patent/AU2009262219B2/en not_active Ceased
- 2009-06-25 JP JP2011516635A patent/JP5357965B2/ja not_active Expired - Fee Related
- 2009-06-25 PL PL09770985T patent/PL2323983T3/pl unknown
- 2009-06-25 CA CA2729016A patent/CA2729016A1/en not_active Abandoned
- 2009-06-25 DK DK09770985.1T patent/DK2323983T3/da active
- 2009-06-25 MX MX2010013664A patent/MX2010013664A/es active IP Right Grant
- 2009-06-25 EA EA201100088A patent/EA021224B1/ru not_active IP Right Cessation
-
2010
- 2010-12-07 IL IL209832A patent/IL209832A/en not_active IP Right Cessation
- 2010-12-14 CO CO10157214A patent/CO6321247A2/es active IP Right Grant
- 2010-12-24 CL CL2010001566A patent/CL2010001566A1/es unknown
-
2012
- 2012-09-27 US US13/628,180 patent/US8633226B2/en active Active
-
2014
- 2014-03-28 CY CY20141100231T patent/CY1114994T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140071T1 (hr) | Derivat piperidinila kao modulator aktivnosti receptora kemokina | |
| US20070010523A1 (en) | Azaindazole compounds and methods of use | |
| Jones et al. | Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase | |
| US20060134767A1 (en) | Mitotic kinesin binding site | |
| HRP20161641T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
| EP1579186A4 (en) | IDENTIFYING KINASE INHIBITORS | |
| Rana et al. | Repurposing of Fluvastatin against Candida albicans CYP450 lanosterol 14 α-demethylase, a target enzyme for antifungal therapy: an In silico and In vitro study | |
| TWI348102B (en) | Architecture and method for managing the sharing of logical resources among separate partitions of a logically partitioned computer system | |
| AU744444B2 (en) | Identification of drugs using complementary combinatorial libraries | |
| BR9808464A (pt) | Sistema e método para recuperação de hidratos | |
| WO1998019162A9 (en) | Identification of drugs using complementary combinatorial libraries | |
| AU2003286703A1 (en) | Process for assessing inhibition of petroleum corrosion | |
| Gitto et al. | Synthesis and evaluation of pharmacological profile of 1-aryl-6, 7-dimethoxy-3, 4-dihydroisoquinoline-2 (1H)-sulfonamides | |
| CA2777032A1 (en) | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity | |
| Wang et al. | Rational design of small-sized peptidomimetic inhibitors disrupting protein–protein interaction | |
| Hashimoto et al. | Thalidomide as a multi-target drug and its application as a template for drug design | |
| FR2884443B1 (fr) | Reacteur de laboratoire pour l'etude de reactions en phase gaz et liquide | |
| Liao et al. | Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA | |
| Abu Khalaf et al. | Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors | |
| Wichapong et al. | Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors | |
| Zeyen et al. | Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells | |
| Huryn et al. | Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists | |
| Argade et al. | Design, synthesis and biological evaluation of γ-lactam hydroxamate based TACE inhibitors | |
| Sireeshaa et al. | In Silico Admet Prediction and Molecular Docking Studies in the Design of New Therapeutic Agents Targeting PIM 1 Kinase | |
| Norman | Indole-based CRTH2 antagonists: OXAGEN LTD: GB02407318, WO2005040112, WO2005040114 & WO2005044260 |